The breath-based biopsy firm is collaborating with Renji Hospital to conduct a clinical trial into the early detection of lung cancer in China.
Under new ownership, the immunology and allergy testing laboratory is looking to raise its profile in the US and overseas.
The new factory will be the company’s first in vitro diagnostic reagent plant in the Asia Pacific region, producing clinical chemistry and immunoassay reagents.
Since purchasing the bioscience unit of Sequenom four years ago, Agena has followed global growth by pushing into more clinical labs in China, as well as Europe.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The expansion is motivated by increasing market demands and the success of current customer immunoassay development projects.
The firm said that it will manufacture assays for its next-generation immunoassay and clinical chemistry system at an expanded facility.